Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on investing in life science companies that advance human health. Domain's focused network, deep experience, and dependable reputation have made it one of the top privateequity groups participating in healthcare investing. With more than $2.7 billion in capital raised, Domain invests in three major segments: pharmaceuticals, diagnostics, and medical devices. The partners of Domain have a total of more than 270 personyears of experience among them in the healthcare and venture capital industries and have been involved in the formation and growth of more than 250 life sciences companies. Representative past investments include Amgen, Amylin Pharmaceuticals, Cerexa, Biosite, Dura Pharmaceuticals, Pharmion and Volcano. Domain has offices in Princeton, N.J. and San Diego.
A subsidiary of the Business Development Bank of Canada (BDC), BDC Capital offers a full spectrum of specialized financing and investment solutions to help Canadian entrepreneurs achieve their full growth potential. With more than $1 billion under management, BDC Capital takes a strategic, patient approach to nurture companies’ development over the long term.
CTI Life Sciences
CTI is a Montrealbased limited partnership making venture capital investments in high quality emerging life sciences companies at the startup and clinical development stage primarily in Canada. CTI has a diverse team of professionals in science and finance with extensive experience in the biotechnology and the pharmaceutical industries. The Fund works closely with entrepreneurs and researchers to increase the value of young companies.
Ontario Emerging Technologies Fund
The Ontario Emerging Technologies Fund (OETF), is a direct investment fund established in 2009 by the Province of Ontario and administered by the Ontario Capital Growth Corporation (OCGC), an agency of the Ministry of Economic Development and Innovation. The OETF is a $250 million fund that coinvests alongside qualified investors in innovative, high- growth, private Ontario companies. The fund focuses on investments in Ontario companies in three sectors: clean technology, life sciences and advanced health technologies, and digital media and information and communications technology.
QIAGEN is a leading provider of sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research. The company has developed and markets more than 500 consumable products and automated solutions. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. QIAGEN employs more than 3,600 people in over 35 locations worldwide, and with over $US 3 billion in market cap and over $US 1 billion in 2010 revenues, is one of the preeminent players in this space.